Five Prime Therapeutics, Inc.:製薬企業の医薬品パイプライン動向2014

◆英語タイトル:Five Prime Therapeutics, Inc. - Product Pipeline Review - 2014
◆商品コード:GMDHC06343CDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年9月22日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥472,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Five Prime Therapeutics, Inc. – Product Pipeline Review – 2014

Summary

Global Markets Direct’s, ‘Five Prime Therapeutics, Inc. – Product Pipeline Review – 2014’, provides an overview of the Five Prime Therapeutics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Five Prime Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Five Prime Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Five Prime Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Five Prime Therapeutics, Inc.’s pipeline products

Reasons to buy

- Evaluate Five Prime Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Five Prime Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Five Prime Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Five Prime Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Five Prime Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Five Prime Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Five Prime Therapeutics, Inc. Snapshot 5
Five Prime Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Five Prime Therapeutics, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
Five Prime Therapeutics, Inc. – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Pipeline Products – Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products – Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Five Prime Therapeutics, Inc. – Pipeline Products Glance 15
Five Prime Therapeutics, Inc. – Clinical Stage Pipeline Products 15
Phase I Products/Combination Treatment Modalities 15
Five Prime Therapeutics, Inc. – Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Five Prime Therapeutics, Inc. – Drug Profiles 18
FP-1039 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
FPA-008 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
FP-1069 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
FPA-144 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Antibodies for Solid Tumors 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibodies for Cancer 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Proteins For Asthma and Chronic Obstructive Pulmonary Disease 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Proteins for Central Nervous System Disorders 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Proteins for Fibrosis Related Inflammatory Diseases 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Five Prime Therapeutics, Inc. – Pipeline Analysis 29
Five Prime Therapeutics, Inc. – Pipeline Products by Target 29
Five Prime Therapeutics, Inc. – Pipeline Products by Route of Administration 30
Five Prime Therapeutics, Inc. – Pipeline Products by Molecule Type 31
Five Prime Therapeutics, Inc. – Pipeline Products by Mechanism of Action 32
Five Prime Therapeutics, Inc. – Recent Pipeline Updates 33
Five Prime Therapeutics, Inc. – Dormant Projects 35
Five Prime Therapeutics, Inc. – Locations And Subsidiaries 36
Head Office 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables
Five Prime Therapeutics, Inc., Key Information 5
Five Prime Therapeutics, Inc., Key Facts 5
Five Prime Therapeutics, Inc. - Pipeline by Indication, 2014 8
Five Prime Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9
Five Prime Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10
Five Prime Therapeutics, Inc. - Partnered Products in Pipeline, 2014 11
Five Prime Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12
Five Prime Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2014 13
Five Prime Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14
Five Prime Therapeutics, Inc. - Phase I, 2014 15
Five Prime Therapeutics, Inc. - Preclinical, 2014 16
Five Prime Therapeutics, Inc. - Discovery, 2014 17
Five Prime Therapeutics, Inc. - Pipeline by Target, 2014 29
Five Prime Therapeutics, Inc. - Pipeline by Route of Administration, 2014 30
Five Prime Therapeutics, Inc. - Pipeline by Molecule Type, 2014 31
Five Prime Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 32
Five Prime Therapeutics, Inc. - Recent Pipeline Updates, 2014 33
Five Prime Therapeutics, Inc. - - Dormant Developmental Projects,2014 35

List of Figures
Five Prime Therapeutics, Inc. - Pipeline by Top 10 Indication, 2014 7
Five Prime Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9
Five Prime Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10
Five Prime Therapeutics, Inc. - Pipeline by Top 10 Target, 2014 29
Five Prime Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2014 30
Five Prime Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2014 31
Five Prime Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 32

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[Five Prime Therapeutics, Inc.:製薬企業の医薬品パイプライン動向2014]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆